Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ronidazole – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ronidazole market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Avian and companion animal protozoal infections (Trichomonas, Histomonas, Giardia) cause significant morbidity and economic loss – but treatment options are limited due to resistance and safety concerns. Ronidazole solves this as a nitroimidazole antimicrobial with potent antiprotozoal activity, used in poultry, pigeons, and companion animals. Key challenges include potential neurotoxicity, strict dosing requirements, and regulatory restrictions in food-producing animals.
The global market for Ronidazole was estimated to be worth US$ 18.99 million in 2025 and is projected to reach US$ 25.08 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global production reached approximately 652,140 units, with an average selling price of US$ 29.1 per unit.
Ronidazole is a nitroimidazole-class antimicrobial and antiprotozoal agent used primarily in veterinary medicine to treat infections caused by anaerobic bacteria and certain protozoa, such as Trichomonas and Histomonas species. It functions by penetrating microbial cells and disrupting DNA synthesis through reduction of its nitro group, leading to cell death. Ronidazole is commonly used in birds (especially poultry and pigeons) and companion animals like dogs and cats for conditions such as histomoniasis (blackhead disease) and giardiasis. Due to its potential toxicity and possible carcinogenicity, it is not approved for use in food-producing animals in many countries and is handled with caution. The compound is typically administered orally and requires strict dosage control to minimize side effects, including neurological toxicity.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098356/ronidazole
Market Segmentation & Key Players
The Ronidazole market is segmented as below:
Leading Suppliers: Glentham Life Sciences, Cayman Chemical, Fengchen Group, Nordic Biosite, Manus Aktteva Biopharma LLP, Simson Pharma Limited, Menadiona.
Segment by Type: Powder | Solution | Tablet
Segment by Application: Poultry Farming | Racing Pigeons and Ornamental Birds | Other
Exclusive Industry Insights
Discrete API synthesis: Ronidazole is manufactured via nitroimidazole chemical synthesis, requiring strict quality control for purity (>98%) and residual solvents. API is then formulated into powder (for mixing with feed/water), solution (oral suspension), or tablets (individual dosing).
Technical differentiation – formulation types:
- Powder (48% revenue): Bulk form for mixing into feed or drinking water. Preferred for poultry farming (mass medication). Largest segment.
- Solution (32% revenue): Ready-to-use oral suspension. For pigeons, ornamental birds, and small companion animals.
- Tablet (20% revenue): Individual dosing for dogs, cats, and birds. Highest value per unit, fastest-growing (CAGR 5.2%).
Recent 6-month data (Oct 2025 – Mar 2026):
- Poultry farming largest application (52% revenue), despite regulatory restrictions in many countries (US, EU banned for food animals).
- Racing pigeons segment fastest-growing (CAGR 5.5%), driven by trichomoniasis prevention in competitive birds.
- Average price increased 6% due to raw material cost inflation.
User case – Racing pigeon breeder (Belgium, 500 birds/year): Using ronidazole solution (50mg/kg) for 5-day course to treat trichomoniasis reduced flock infection rate from 35% to 8% during racing season. Treatment cost: US$ 2.50 per bird; prevented loss of racing performance valued at US$ 500+ per bird.
Application insights: Poultry Farming (52%) – histomoniasis (blackhead disease) in turkeys and chickens, trichomoniasis in breeding flocks. Racing Pigeons & Ornamental Birds (35%) – canker (trichomoniasis), routine prevention during racing season. Other (13%) – companion animals (dogs: giardiasis, cats: Tritrichomonas foetus), exotic birds.
Safety considerations:
- Neurotoxicity risk: At high doses (>/= 100mg/kg) or prolonged use, potential for neurological signs (ataxia, seizures).
- Contraindications: Not for use in food-producing animals in US, EU, Canada, Japan.
- Withdrawal periods: Required in countries where approved (typically 14–21 days for meat, 5–7 days for eggs).
Regional snapshot: Europe leads with 42% revenue share (racing pigeon culture). Asia-Pacific holds 32% (poultry production, less restrictive regulations). North America 18% (restricted use in non-food animals only).
Conclusion
The ronidazole market is niche but stable, driven by racing pigeon health, companion animal giardiasis, and poultry histomoniasis treatment where permitted. Success depends on regulatory compliance, dosing precision, and safety monitoring. The projected US$ 25.1 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
